Pre-made Abelacimab benchmark antibody ( Whole mAb, anti-F11/F11 mRNA therapeutic antibody, Anti-FXI/PTA Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Abelacimab biosimilar, Whole mAb, Anti-F11 Antibody: Anti-FXI/PTA therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Abelacimab (previously known as MAA 868) is a fully human, factor XI monoclonal antibody, being developed by Anthos Therapeutics under the license from Novartis, for the prevention of cardiovascular disorders including stroke due to thrombosis and thromboembolism in patients with atrial fibrillation.
| Products Name (INN Index) | Pre-Made Abelacimab biosimilar, Whole mAb, Anti-F11 Antibody: Anti-FXI/PTA therapeutic antibody |
|---|---|
| INN Name | Abelacimab |
| Target | F11 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | 6r8x:CB |
| Year Proposed | 2018 |
| Year Recommended | 2019 |
| Companies | Novartis |
| Conditions Approved | NA |
| Conditions Active | Venous Thromboembolism, Stroke,Thrombosis |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | F11 |
| Package |
